Entera Bio Ltd Market Cap ($434.59 Million)
Market Cap & Net Worth: Entera Bio Ltd (ENTX)
Entera Bio Ltd market cap. Entera Bio Ltd (NASDAQ:ENTX) has a market capitalization of $434.59 Million ($434.59 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12664 globally and #3156 in its home market, demonstrating a 5.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Entera Bio Ltd's stock price $3.09 by its total outstanding shares 173834271 (173.83 Million). Also see ENTX cash flow metrics for how efficiently the company converts equity into cash flow.
Entera Bio Ltd Market Cap History (2018–2026)
Entera Bio Ltd market cap history from 2018 to 2026. Data shows change from $530.19 Million to $537.15 Million (-8.14% CAGR). Check ENTX stock price for real-time trading data and today's change.
Index Memberships
Entera Bio Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.02% | #343 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1260 of 3165 |
Weight: Entera Bio Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Entera Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Entera Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ENTX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
8029.49x
Entera Bio Ltd's market cap is 8029.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $530.19 Million | $500.00K | -$10.30 Million | 1060.39x | N/A |
| 2019 | $372.01 Million | $236.00K | -$10.79 Million | 1576.29x | N/A |
| 2020 | $187.74 Million | $365.00K | -$9.98 Million | 514.36x | N/A |
| 2021 | $489.34 Million | $571.00K | -$12.19 Million | 856.99x | N/A |
| 2022 | $126.90 Million | $134.00K | -$13.07 Million | 947.01x | N/A |
| 2023 | $104.30 Million | $14.00K | -$8.89 Million | 7450.04x | N/A |
| 2024 | $368.53 Million | $181.00K | -$9.54 Million | 2036.07x | N/A |
| 2025 | $337.24 Million | $42.00K | -$11.44 Million | 8029.49x | N/A |
Competitor Companies of ENTX by Market Capitalization
Companies near Entera Bio Ltd in the global market cap rankings as of November 4, 2026. Also see ENTX asset base for a full breakdown of the balance sheet.
Key companies related to Entera Bio Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Entera Bio Ltd (2018–2026)
Market capitalization of Entera Bio Ltd from 2018 to today. Between 2018 and today, Entera Bio Ltd's market cap moved from $530.19 Million to $ 537.15 Million, with a yearly change of -8.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $537.15 Million | +59.28% |
| 2025 | $337.24 Million | -8.49% |
| 2024 | $368.53 Million | +253.33% |
| 2023 | $104.30 Million | -17.81% |
| 2022 | $126.90 Million | -74.07% |
| 2021 | $489.34 Million | +160.65% |
| 2020 | $187.74 Million | -49.53% |
| 2019 | $372.01 Million | -29.84% |
| 2018 | $530.19 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Entera Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $434.59 Million USD |
| MoneyControl | $434.59 Million USD |
| MarketWatch | $434.59 Million USD |
| marketcap.company | $434.59 Million USD |
| Reuters | $434.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more